Sonnet biotherapeutics announces abstract accepted for presentation by a key opinion leader at the 2023 connective tissue oncology society (ctos) annual meeting

Princeton, nj / accesswire / october 17, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that previously announced interim data from the sb101 clinical trial of the company's proprietary fully human albuminbinding (fhab) candidate, son-1010 (il12- fhab), will be presented by dr. sant chawla, a key opinion leader in the field of sarcoma research, at the upcoming connective tissue oncology society annual meeting 2023, which will be held november 1‑4, in dublin, ireland. "we are excited to be part of sonnet's first-in-human use of son-1010 in the cancer setting that is being studied in the sb101 trial," said sant chawla, md, principal investigator and director of the sarcoma center in santa monica, california.
SONN Ratings Summary
SONN Quant Ranking